Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday ...

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

"Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality ...

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded ...

Scope-X, an expanded version of the Seq-Scope spatial transcriptomics method. The technique overcomes diffusion limits and enables higher-resolution mapping of mRNA within cells.

Illumina’s fair value estimate has been adjusted slightly, moving from US$135.94 to US$136.05, signaling only a very modest change in the modeled price target. That small shift sits against a backdrop ...

Faced with a slumping stock and growing competition in the next-generation sequencing market it continues to dominate, Illumina this past week committed to delivering high single-digit revenue ...

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem ...